Page 13 - 2023-08-中国全科医学

·910· http: //www.chinagp.net E-mail: zgqkyx@chinagp.net.cn March 2023, Vol.26 No.8

drug delivery［J］. Eur J Pharm Sci，2013，50（3/4）：400- ［50］GURUNATHAN S，KANG M H，KIM J H. A comprehensive
409. DOI：10.1016/j.ejps.2013.08.026. review on factors influences biogenesis，functions，therapeutic
［37］HU Y C，ZHI Z Z，WANG T Y，et al. Incorporation of and clinical implications of exosomes［J］. Int J Nanomedicine，
indomethacin nanoparticles into 3-D ordered macroporous silica 2021，16：1281-1312. DOI：10.2147/IJN.S291956.
for enhanced dissolution and reduced gastric irritancy［J］. Eur J ［51］MA X T，WANG J J，LI J，et al. Loading miR-210 in endothelial
Pharm Biopharm，2011，79（3）：544-551. DOI：10.1016/j. progenitor cells derived exosomes boosts their beneficial effects
ejpb.2011.07.001. on hypoxia/reoxygeneation-injured human endothelial cells via
［38］MELLAERTS R，MOLS R，JAMMAER J A，et al. Increasing the protecting mitochondrial function［J］. Cell Physiol Biochem，
oral bioavailability of the poorly water soluble drug itraconazole with 2018，46（2）：664-675. DOI：10.1159/000488635.
ordered mesoporous silica［J］. Eur J Pharm Biopharm，2008，69 ［52］CHEN A Q，GAO X F，WANG Z M，et al. Therapeutic
（1）：223-230. DOI：10.1016/j.ejpb.2007.11.006. exosomes in prognosis and developments of coronary artery
［39］WANG Y Z，SUN L Z，JIANG T Y，et al. The investigation disease［J］. Front Cardiovasc Med，2021，8：691548. DOI：
of MCM-48-type and MCM-41-type mesoporous silica as oral 10.3389/fcvm.2021.691548.
solid dispersion carriers for water insoluble cilostazol［J］. ［53］BANIZS A B，HUANG T，DRYDEN K，et al. In vitro evaluation
Drug Dev Ind Pharm，2014，40（6）：819-828. DOI： of endothelial exosomes as carriers for small interfering ribonucleic
10.3109/03639045.2013.788013. acid delivery［J］. Int J Nanomedicine，2014，9：4223-4230.
［40］HU Y C. 3D cubic mesoporous silica microsphere as a carrier for DOI：10.2147/IJN.S64267.
poorly soluble drug carvedilol［J］. Microporous Mesoporous ［54］HERGENREIDER E，HEYDT S，TRÉGUER K，et al.
Mater，2012，147（1）：94-101. DOI：10.1016/j. Atheroprotective communication between endothelial cells and
micromeso.2011.06.001. smooth muscle cells through miRNAs［J］. Nat Cell Biol，2012，
［41］ZHANG Y Z，ZHI Z Z，JIANG T Y，et al. Spherical mesoporous 14（3）：249-256. DOI：10.1038/ncb2441.
silica nanoparticles for loading and release of the poorly water- ［55］WU G H，ZHANG J F，ZHAO Q R，et al. Molecularly engineered
soluble drug telmisartan［J］. J Control Release，2010，145（3）： macrophage-derived exosomes with inflammation tropism and
257-263. DOI：10.1016/j.jconrel.2010.04.029. intrinsic heme biosynthesis for atherosclerosis treatment［J］.
［42］WU M L，LI X，GUO Q，et al. Magnetic mesoporous silica Angew Chem Int Ed Engl，2020，59（10）：4068-4074. DOI：
nanoparticles-aided dual MR/NIRF imaging to identify macrophage 10.1002/anie.201913700.
enrichment in atherosclerotic plaques［J］. Nanomed-Nanotechnol ［56］MOGHIMI S M，SIMBERG D. Complement activation turnover on
Biol Med，2021，32：102330. DOI：10.1016/j.nano.2020.102330. surfaces of nanoparticles［J］. Nano Today，2017，15：8-10.
［43］BELDMAN T J，SENDERS M L，ALAARG A，et al. Hyaluronan DOI：10.1016/j.nantod.2017.03.001.
nanoparticles selectively target plaque-associated macrophages ［57］CHEN F F，WANG G K，GRIFFIN J I，et al. Complement
and improve plaque stability in atherosclerosis［J］. ACS Nano， proteins bind to nanoparticle protein Corona and undergo dynamic
2017，11（6）：5785-5799. DOI：10.1021/acsnano.7b01385. exchange in vivo［J］. Nat Nanotechnol，2017，12（4）：387-
［44］LEWIS D R，PETERSEN L K，YORK A W，et al. Sugar-based 393. DOI：10.1038/nnano.2016.269.
amphiphilic nanoparticles arrest atherosclerosis in vivo［J］. ［58］SZEBENI J，BEDOCS P，ROZSNYAY Z，et al. Liposome-
Proc Natl Acad Sci USA，2015，112（9）：2693-2698. DOI： induced complement activation and related cardiopulmonary
10.1073/pnas.1424594112. distress in pigs：factors promoting reactogenicity of Doxil and
［45］QIE Y Q，YUAN H F，VON ROEMELING C A，et al. Surface AmBisome［J］. Nanomed-Nanotechnol Biol Med，2012，8（2）：
modification of nanoparticles enables selective evasion of phagocytic 176-184. DOI：10.1016/j.nano.2011.06.003.
clearance by distinct macrophage phenotypes［J］. Sci Rep，2016，6： ［59］WANG G K，CHEN F F，BANDA N K，et al. Activation of human
26269. DOI：10.1038/srep26269. complement system by dextran-coated iron oxide nanoparticles
［46］VOLPE C M O，VILLAR-DELFINO P H，DOS ANJOS P M F， is not affected by dextran/Fe ratio，hydroxyl modifications，
et al. Cellular death，reactive oxygen species （ROS） and diabetic and crosslinking［J］. Front Immunol，2016，7：418. DOI：
complications［J］. Cell Death Dis，2018，9（2）：119. DOI： 10.3389/fimmu.2016.00418.
10.1038/s41419-017-0135-z. ［60］BANDA N K，MEHTA G，CHAO Y，et al. Mechanisms of
［47］LI J M，NEWBURGER P E，GOUNIS M J，et al. Local arterial complement activation by dextran-coated superparamagnetic iron
nanoparticle delivery of siRNA for NOX2 knockdown to prevent oxide （SPIO） nanoworms in mouse versus human serum［J］.
restenosis in an atherosclerotic rat model［J］. Gene Ther，2010， Part Fibre Toxicol，2014，11：64. DOI：10.1186/s12989-014-
17（10）：1279-1287. DOI：10.1038/gt.2010.69. 0064-2.
［48］MOORE K J，TABAS I. Macrophages in the pathogenesis of ［61］NORDIN J Z，LEE Y，VADER P，et al. Ultrafiltration with
atherosclerosis［J］. Cell，2011，145（3）：341-355. DOI： size-exclusion liquid chromatography for high yield isolation of
10.1016/j.cell.2011.04.005. extracellular vesicles preserving intact biophysical and functional
［49］POON C，GALLO J，JOO J，et al. Hybrid，metal oxide-peptide properties［J］. Nanomed-Nanotechnol Biol Med，2015，11（4）：
amphiphile micelles for molecular magnetic resonance imaging of 879-883. DOI：10.1016/j.nano.2015.01.003.
atherosclerosis［J］. J Nanobiotechnology，2018，16（1）：92. （收稿日期：2022-10-14；修回日期：2022-11-30）
DOI：10.1186/s12951-018-0420-8. （本文编辑：贾萌萌）